CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Moderna, Inc. - MRNA CFD

164.11
3.32%
1.28
Low: 163.6
High: 169.94
Market Trading Hours* (UTC) Opens on Thursday at 09:10

Mon: 09:10 - 00:00

Tue - Thu: 00:00 - 01:00 09:10 - 00:00

Fri: 00:00 - 01:00 09:10 - 22:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.28
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 169.74
Open* 169.74
1-Year Change* 11.82%
Day's Range* 163.6 - 169.94
52 wk Range 115.03-217.25
Average Volume (10 days) 3.46M
Average Volume (3 months) 101.47M
Market Cap 65.41B
P/E Ratio 6.16
Shares Outstanding 384.18M
Revenue 21.39B
EPS 27.65
Dividend (Yield %) N/A
Beta 1.64
Next Earnings Date Feb 23, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 8, 2023 169.74 -0.06 -0.04% 169.80 169.92 169.74
Feb 7, 2023 169.74 -0.13 -0.08% 169.87 171.31 166.47
Feb 6, 2023 169.87 -0.57 -0.33% 170.44 173.76 169.00
Feb 3, 2023 172.48 -2.20 -1.26% 174.68 178.08 171.44
Feb 2, 2023 174.68 1.75 1.01% 172.93 177.42 169.96
Feb 1, 2023 173.07 -1.51 -0.86% 174.58 175.36 166.70
Jan 31, 2023 174.43 -5.44 -3.02% 179.87 179.91 173.18
Jan 30, 2023 179.42 -7.07 -3.79% 186.49 187.72 179.33
Jan 27, 2023 188.38 -2.63 -1.38% 191.01 192.94 187.70
Jan 26, 2023 191.01 -1.50 -0.78% 192.51 194.25 186.93
Jan 25, 2023 190.98 -2.88 -1.49% 193.86 194.56 189.13
Jan 24, 2023 193.34 -2.12 -1.08% 195.46 196.37 192.42
Jan 23, 2023 195.46 3.49 1.82% 191.97 198.08 190.00
Jan 20, 2023 192.72 2.85 1.50% 189.87 193.94 187.78
Jan 19, 2023 189.96 -5.88 -3.00% 195.84 196.46 189.55
Jan 18, 2023 195.85 -3.98 -1.99% 199.83 206.81 194.38
Jan 17, 2023 199.84 10.34 5.46% 189.50 205.64 186.66
Jan 13, 2023 190.36 3.41 1.82% 186.95 191.44 184.21
Jan 12, 2023 186.95 2.23 1.21% 184.72 188.39 178.60
Jan 11, 2023 184.73 -3.83 -2.03% 188.56 190.18 182.07

Moderna, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 108.396 205.825 135.068 60.209 803.395 18471
Revenue 108.396 205.825 135.068 60.209 803.395 18471
Total Operating Expense 332.167 475.181 548.334 605.929 1566.54 5175
Selling/General/Admin. Expenses, Total 57.45 64.722 94.252 109.62 188.267 567
Research & Development 274.717 410.459 454.082 496.309 1370.34 1991
Operating Income -223.771 -269.356 -413.266 -545.72 -763.144 13296
Interest Income (Expense), Net Non-Operating 8.603 13.36 23.958 32.241 16.125 1
Net Income Before Taxes -215.168 -255.996 -384.408 -514.716 -744.513 13285
Net Income After Taxes -216.211 -255.916 -384.734 -514.021 -747.064 12202
Net Income Before Extra. Items -216.211 -255.916 -384.734 -514.021 -747.064 12202
Net Income -216.211 -255.916 -384.734 -514.021 -747.064 12202
Total Adjustments to Net Income -14.103 -13.925 -17.123 0 0
Income Available to Common Excl. Extra. Items -230.314 -269.841 -401.857 -514.021 -747.064 12202
Income Available to Common Incl. Extra. Items -230.314 -269.841 -401.857 -514.021 -747.064 12202
Diluted Net Income -230.314 -269.841 -401.857 -514.021 -747.064 12202
Diluted Weighted Average Shares 324.411 324.411 328.799 330.802 381.333 431
Diluted EPS Excluding Extraordinary Items -0.70994 -0.83179 -1.2222 -1.55386 -1.95909 28.3109
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.70994 -0.83179 -1.2222 -1.55386 -1.95909 28.3109
Other, Net 4.9 -1.237 2.506 -12
Cost of Revenue, Total 7.933 2617
Gross Profit 795.462 15854
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 1937 4354 4969 7211 6066
Revenue 1937 4354 4969 7211 6066
Cost of Revenue, Total 193 750 722 952 1017
Gross Profit 1744 3604 4247 6259 5049
Total Operating Expense 671 1292 1411 1801 1839
Selling/General/Admin. Expenses, Total 77 121 168 201 268
Research & Development 401 421 521 648 554
Operating Income 1266 3062 3558 5410 4227
Interest Income (Expense), Net Non-Operating 1 0 0 0 3
Other, Net -7 1 -6 0 -1
Net Income Before Taxes 1260 3063 3552 5410 4229
Net Income After Taxes 1221 2780 3333 4868 3657
Net Income Before Extra. Items 1221 2780 3333 4868 3657
Net Income 1221 2780 3333 4868 3657
Income Available to Common Excl. Extra. Items 1221 2780 3333 4868 3657
Income Available to Common Incl. Extra. Items 1221 2780 3333 4868 3657
Diluted Net Income 1221 2780 3333 4868 3657
Diluted Weighted Average Shares 430 431 434 431 426
Diluted EPS Excluding Extraordinary Items 2.83953 6.45012 7.67972 11.2947 8.58451
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 2.83953 6.45012 7.67972 11.2947 8.58451
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 1087.15 783.223 1563.01 1128.8 6297.88 16071
Cash and Short Term Investments 1058.14 756.029 1521.43 1103 4607.61 10727
Cash & Equivalents 50.08 134.859 658.364 235.876 2623.85 6848
Short Term Investments 1008.06 621.17 863.063 867.124 1983.76 3879
Total Receivables, Net 17.951 16.656 30.583 16.297 1410.53 3296
Accounts Receivable - Trade, Net 13.523 13.417 12.585 5.369 1390.56 3175
Prepaid Expenses 11.063 9.587 10.401 8.475 232.185 531
Other Current Assets, Total 0 0.951 0.595 1.032 1.032 76
Total Assets 1417.16 1084.49 1962.15 1589.42 7336.75 24669
Property/Plant/Equipment, Total - Net 81.207 139.031 211.977 287.909 387.09 1383
Property/Plant/Equipment, Total - Gross 109.016 187.062 276.433 382.493 506.751 1735
Accumulated Depreciation, Total -27.809 -48.031 -64.456 -94.584 -119.661 -352
Long Term Investments 236.569 145.851 172.99 159.987 638.848 6843
Other Long Term Assets, Total 12.233 16.384 14.176 12.722 12.933 372
Total Current Liabilities 162.802 191.461 222.803 143.115 4388.81 9128
Accounts Payable 28.157 20.725 31.21 7.09 18.359 302
Accrued Expenses 25.052 72.715 79.073 71.236 475.563 1518
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 109.593 98.021 112.52 64.789 3870.56 7143
Total Liabilities 575.31 459.193 431.908 414.612 4775.38 10524
Total Long Term Debt 12.5 15.687 33.489 38.689 109.874 599
Capital Lease Obligations 12.5 15.687 33.489 38.689 109.874 599
Other Liabilities, Total 400.008 252.045 175.616 232.808 276.693 797
Total Equity 841.851 625.296 1530.24 1174.81 2561.38 14145
Preferred Stock - Non Redeemable, Net 1176.66 1176.66 0
Common Stock 0.006 0.006 0.033 0.034 0.04 0
Additional Paid-In Capital 31.305 71.679 2538.16 2669.43 4801.85 4211
Retained Earnings (Accumulated Deficit) -365.718 -621.893 -1006.63 -1496.45 -2243.52 9958
Other Equity, Total -0.403 -1.157 -24
Total Liabilities & Shareholders’ Equity 1417.16 1084.49 1962.15 1589.42 7336.75 24669
Total Common Shares Outstanding 324.411 324.411 328.799 336.537 398.788 403
Unrealized Gain (Loss) -1.32 1.804 3.004
Redeemable Preferred Stock 0 0 0
Total Inventory 46.527 1441
Current Port. of LT Debt/Capital Leases 24.328 165
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 11703 10969 13425 16071 16350
Cash and Short Term Investments 7735 7990 8906 10727 10115
Cash & Equivalents 5442 5603 5550 6848 5048
Short Term Investments 2293 2387 3356 3879 5067
Total Receivables, Net 3228 2071 3199 3296 3364
Accounts Receivable - Trade, Net 3210 2020 3142 3175 3173
Total Inventory 494 643 965 1441 1942
Prepaid Expenses 246 197 261 531 858
Total Assets 12694 16153 20923 24669 27609
Property/Plant/Equipment, Total - Net 461 898 960 1383 1473
Property/Plant/Equipment, Total - Gross 596 1102 1234 1735 1904
Accumulated Depreciation, Total -135 -204 -274 -352 -431
Long Term Investments 468 4207 6442 6843 9171
Other Long Term Assets, Total 62 79 96 372 615
Total Current Liabilities 8441 8840 9957 9128 9238
Accounts Payable 8 77 87 302 199
Accrued Expenses 760 859 1098 1518 1654
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 45 159 218 165 160
Other Current Liabilities, Total 7628 7745 8554 7143 7225
Total Liabilities 8856 9449 10799 10524 10534
Total Long Term Debt 138 328 238 599 646
Capital Lease Obligations 138 328 238 599 646
Other Liabilities, Total 277 281 604 797 650
Total Equity 3838 6704 10124 14145 17075
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.0401 0.0403 0.0405 0 0.04
Additional Paid-In Capital 4860 4931 5003 4211 3644
Retained Earnings (Accumulated Deficit) -1023 1757 5090 9958 13615
Unrealized Gain (Loss) 1 -211
Other Equity, Total -0.0401 15.9597 30.9595 -24 26.96
Total Liabilities & Shareholders’ Equity 12694 16153 20923 24669 27609
Total Common Shares Outstanding 401 403 405 403 400
Other Current Assets, Total 68 94 76 71
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -216.211 -255.916 -384.734 -514.021 -747.064 12202
Cash From Operating Activities 66.734 -331.484 -330.865 -458.968 2026.97 13620
Cash From Operating Activities 15.114 20.537 24.862 31.021 31.251 232
Deferred Taxes 0.288 -318
Non-Cash Items 41.838 41.141 71.59 77.696 165.73 196
Cash Taxes Paid 0.905 0.398 0.294 0.416 0.572 480
Changes in Working Capital 225.705 -137.246 -42.583 -53.664 2577.05 1308
Cash From Investing Activities -648.607 417.364 -373.094 -14.945 -1671.93 -8523
Capital Expenditures -33.144 -58.401 -105.766 -31.554 -67.448 -284
Other Investing Cash Flow Items, Total -615.463 475.765 -267.328 16.609 -1604.48 -8239
Cash From Financing Activities 472.91 0.168 1226.84 51.121 2033.19 -873
Financing Cash Flow Items -0.633 1.241 11.635 0.971 0
Issuance (Retirement) of Stock, Net 473.543 0.212 1217.38 50.15 2039.41 -733
Issuance (Retirement) of Debt, Net 0 -1.285 -2.175 0 -6.215 -140
Net Change in Cash -108.963 86.048 522.883 -422.792 2388.24 4224
Cash Interest Paid 8.528 14
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1221 4001 7334 12202 3657
Cash From Operating Activities 2971 7034 10310 13620 2763
Cash From Operating Activities 15 84 154 232 79
Deferred Taxes -50 -72 -89 -318 -146
Non-Cash Items 35 78 138 196 62
Changes in Working Capital 1750 2943 2773 1308 -889
Cash From Investing Activities -180 -4058 -7385 -8523 -3921
Capital Expenditures -35 -65 -164 -284 -132
Other Investing Cash Flow Items, Total -145 -3993 -7221 -8239 -3789
Cash From Financing Activities 26 2 0 -873 -642
Issuance (Retirement) of Stock, Net 28 64 96 -733 -611
Issuance (Retirement) of Debt, Net -2 -62 -96 -140 -31
Net Change in Cash 2817 2978 2925 4224 -1800
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Baillie Gifford & Co. Investment Advisor 11.6577 44786746 -493277 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.0988 27272334 -205438 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.4308 17022247 -545268 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.7758 14506066 -260514 2022-09-30 LOW
Flagship Ventures Venture Capital 3.3543 12886743 0 2022-09-30 LOW
Langer (Robert S Jr.) Individual Investor 2.996 11510060 703 2022-04-28
Boston Biotech Ventures, L.L.C. Corporation 2.3558 9050372 0 2022-03-01 LOW
OCHA, L.L.C. Corporation 1.8233 7004880 -80000 2022-03-01 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.6263 6247811 -89880 2022-09-30 LOW
Theleme Partners LLP Hedge Fund 1.5629 6004406 -350000 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.5611 5997327 2604953 2022-09-30 LOW
Coatue Management, L.L.C. Hedge Fund 1.4854 5706504 173 2022-09-30
Bancel (Stephane J) Individual Investor 1.4087 5411946 0 2023-02-02 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.2947 4974009 -150991 2023-01-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.2263 4711101 339752 2022-09-30 LOW
Banque Pictet & Cie S.A. Investment Advisor 0.8021 3081437 57256 2022-12-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.7925 3044449 -45668 2021-12-31 LOW
Capital Research Global Investors Investment Advisor 0.6722 2582471 1461529 2022-12-31 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.6374 2448814 -119997 2022-09-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.6342 2436418 -44023 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+500000+

Traders

93000+

Active clients monthly

$57000000+

Monthly investing volume

$31000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Moderna, Inc. Company profile

Get all the information you need on the Moderna stock price today with Capital.com’s comprehensive chart.

Moderna (MRNA) is a North American clinical-stage biotechnology company. Headquartered in Cambridge, Massachusetts, it specialises in drug discovery and development, as well as vaccine technologies based on messenger RNA (mRNA). The company is working on therapeutics and vaccines for infectious, autoimmune, immuno-oncology and cardiovascular diseases.

Moderna has a number of strategic partnerships with industry-leading names, such as Vertex Pharmaceuticals (VRTX), AstraZeneca (AZN) and Merck & Co (MRK). In 2020, it also worked with Lonza Group (LONN) and Catalent (CTLT) to manufacture its Covid-19 vaccine candidate mRNA-1273. At the end of 2020, the company had 12 programmes in clinical trials and a total of 23 development candidates.

Moderna shares are listed on the Nasdaq Stock Market under the ticker symbol MRNA. The company is a constituent of the NASDAQ-100 Index.

Stay up-to-date with the latest market news and watch the Moderna share price live at Capital.com.

The company was founded in 2010 as Moderna Therapeutics, with the goal of commercialising the research of stem-cell biologist Derrick Rossi. Apart from Rossi, Moderna’s co-founders were Noubar Afeyan, Robert Langer and Kenneth Chien. In August 2018, the company’s name was changed to Moderna.

In November 2020, Moderna’s Covid-19 vaccine candidate, mRNA-1273, showed preliminary evidence of 94.1 per cent efficacy in preventing the disease in a Phase 3 trial. The results led to its submission for emergency use authorisation in the US, Canada and Europe.

In late November, the EU made a deal with Moderna for up to 160 million doses of its vaccine. In December, the US government exercised its option to buy an additional 100 million doses of Moderna’s mRNA-1273, bringing the confirmed order commitment to 200 million doses.

With Capital.com’s Moderna share price chart, you can not only quickly view the current MRNA stock quote, but also trace the company’s share value in historic terms.

Moderna’s long-awaited initial public offering (IPO) happened in December 2018, with the firm selling 26.3 million shares priced at $23 each. At the time, it was the biggest biotech IPO ever. Moderna raised over $600m, valuing the company at $7.5bn (£5.6bn, €6.2bn).

In 2020, MRNA stock has been one of the US market’s best performers. This was due to rising investor enthusiasm over the company’s promising Covid-19 vaccine candidate. After opening the year at $19.57, the MRNA share price was on a hike, peaking at $94.85 in mid July. Within a month, it had dropped to $54.23, but then the stock gained another upside momentum, with its price surging past $100 on November 16. On December 8, the stock closed the trading day at $169.86, representing a year-to-date gain of nearly 770 per cent.

You can go long or short on the company’s shares and trace all the latest ups and downs of the Moderna Inc. stock price using Capital.com’s proprietary trading platform.

Industry: Biotechnology & Medical Research (NEC)

200 Technology Sq
CAMBRIDGE
MASSACHUSETTS 02139-3578
US

Income Statement

  • Annual
  • Quarterly

People also watch

US100

12,525.60 Price
-1.320% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0077%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

22,984.35 Price
-0.950% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Natural Gas

2.46 Price
-6.440% 1D Chg, %
Long position overnight fee -0.1217%
Short position overnight fee 0.0860%
Overnight fee time 22:00 (UTC)
Spread 0.005

XRP/USD

0.40 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00321
video

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading